Friedreich's Ataxia
Also known as: FRDA, Spinocerebellar Degeneration with Cardiomyopathy, Friedreich Ataxia
Friedreich's ataxia (FRDA) is a rare, inherited neurodegenerative disease that causes progressive damage to the nervous system, resulting in symptoms ranging from muscle weakness and speech problems to heart disease. It is primarily caused by a deficiency of the protein frataxin, which leads to mitochondrial dysfunction and iron accumulation in cells, particularly in the spinal cord, peripheral nerves, and cerebellum. The condition typically manifests in childhood or adolescence and leads to increasing disability over time.
Imagine your body's wires are getting tangled, making it hard to walk, talk, and even keep your heart strong. That's kind of like Friedreich's Ataxia. It's a rare disease that makes it difficult for your body to control movement and can cause heart problems. Doctors are working hard to find better ways to help people with this condition.
Signs & Symptoms
- Progressive ataxia (loss of coordination)
- Muscle weakness
- Dysarthria (speech problems)
- Dysphagia (difficulty swallowing)
- Scoliosis
- Cardiomyopathy (heart muscle disease)
- Diabetes mellitus
- Vision impairment
- Hearing loss
- Fatigue
- Nystagmus (involuntary eye movements)
- Loss of reflexes
- Foot deformities (pes cavus, hammer toes)
Treatment Options
Omaveloxolone (Skyclarys)
MODERATELY EFFECTIVE Approved 2023Physical therapy
SUPPORTIVEOccupational therapy
SUPPORTIVESpeech therapy
SUPPORTIVECardiac management (medications, devices)
SUPPORTIVEScoliosis bracing or surgery
SUPPORTIVEDiabetes management (insulin or oral medications)
SUPPORTIVEIdebenone
MODERATELY EFFECTIVEDiagnosis
- Neurological examination
- Genetic testing for FXN gene mutations
- MRI of the brain and spinal cord
- Electrocardiogram (ECG) and echocardiogram
- Nerve conduction studies
- Electromyography (EMG)
- Blood tests (glucose levels, iron studies)
History
Friedreich's ataxia was first described in the 1860s by Nikolaus Friedreich, a German pathologist and neurologist. He characterized the clinical features of the disease in a series of patients, establishing it as a distinct neurological entity. The genetic basis of FRDA was discovered in 1996, with the identification of the FXN gene and the GAA repeat expansion mutation.
Recent Breakthroughs
FDA Approves Omaveloxolone for Friedreich's Ataxia
The FDA approved Omaveloxolone (Skyclarys) as the first treatment specifically for Friedreich's ataxia. This medication has shown to improve neurological function in patients with FRDA by activating Nrf2 pathway.
Gene Therapy Clinical Trials Showing Promise
Early-stage clinical trials are evaluating the safety and efficacy of gene therapy approaches to increase frataxin expression in patients with Friedreich's ataxia. Preliminary results suggest potential for disease modification.